Navigation Links
WARFARIN Study Launched at WellStar Health System to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin
Date:3/1/2011

BOTHELL, Wash., March 1, 2011 /PRNewswire/ -- Iverson Genetic Diagnostics, Inc. announced today that the WARFARIN Study (Warfarin Adverse Event Reduction for Adults Receiving Genetic Testing at Therapy Initiation) was initiated at WellStar Health System in Marietta and other major hospital systems nationwide to assess the utility of genetic testing to determine a personalized warfarin dose for individual patients to reduce their risk of serious bleeding or clotting events. Warfarin, the most commonly prescribed blood thinner worldwide, causes up to 100,000 serious and unnecessary adverse events every year, including thousands of deaths.  Studies have shown that DNA testing can dramatically improve the safety and effectiveness of warfarin, with estimated savings to the U.S. healthcare system of approximately $1.1 billion.Warfarin is prescribed to 2 million patients in the U.S. annually and approximately 20 million Americans use the drug in total.  Warfarin is difficult to dose as patients respond to it differently according to their genetic makeup – too much warfarin can result in severe bleeding, and too little can cause clot formation and increased risk of stroke.  In the past, warfarin dosing relied on trial-and-error, which exposed patients to serious medical risks.  Warfarin is the second most frequent cause of drug-related emergency room visits.

"Georgia is a committed partner in advancing personalized medicine, and we are proud to be the testing ground for research that has the potential to improve health, save lives and lower healthcare costs here in Georgia as well as nationwide," said Chris Cummiskey, Commissioner of the Georgia Department of Economic Development.  

Over the past few years, two genetic variants have been identified that predict an individual's response to warfarin.  Using genetic testing to guide physicians in starting warfarin therapy has
'/>"/>

SOURCE Iverson Genetic Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genetic information personalizes warfarin prescribing
2. WARFARIN Study Launched at Overlake Hospital Medical Center to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. RAND study finds increase in piracy and terrorism at sea
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
7. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
8. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
9. RainDance and Scripps to Collaborate on Targeted Sequencing for Wellderly Study
10. Preliminary Report of American Biotech Labs HIV Study Featured in Inaugural Issue of Journal of the Science of Healing Outcomes
11. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... Clinical Trial Application (CTA) with the United ... seeking regulatory approval to initiate clinical trials for the ... Contingent on the Company receiving CTA regulatory approval, ... to assess the safety, tolerability and dose escalation of ...
(Date:12/22/2014)... , Dec. 22, 2014   Synthetic ... developer of pathogen-specific therapies for serious infections ... the microbiome, today announced positive topline safety ... clinical trial of SYN-004, the Company,s investigational ... Clostridium difficile (C. difficile) infection, ...
(Date:12/22/2014)... , Dec. 22, 2014 GenomeDx Biosciences today ... Prostate Cancer Classifier, a genomic test for prostate cancer, ... high-risk men managed by radical prostatectomy without adjuvant therapy. ... is relatively uncommon, using tumor genomics to identify these ... disease is an important advance. The study has been ...
(Date:12/22/2014)... ITRA Global, one of the largest organizations ... estate, has further expanded its global reach with the ... Western Australia, reports Mylinda Vick, CCIM, Chairman of the ... / ACORPP (Australian Corporate Property and Projects) , is ... services to a wide range of clients in the ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... CALGARY, May 22 /PRNewswire-FirstCall/ - Oncolytics Biotech ... has,successfully transferred cGMP production for REOLYSIN(R) at ... Division of Sigma-Aldrich Corporation.,This follows the successful ... announced,by the Company last year., Yields ...
... AMSTERDAM, The Netherlands, May 22 Amsterdam,Molecular ... field of human gene,therapy, today announced that ... in Rome, Italy, to their advanced small ... of Duchenne,muscular dystrophy (DMD). The combination with ...
... SOUTH SAN FRANCISCO, Calif., May 21 Exelixis,Inc. (Nasdaq: ... and,analyst briefing in conjunction with the 44th Annual Meeting of ... 8:00 p.m. CT,on Monday, June 2, 2008., Participants:, ... Officer -- Michael M. Morrissey, PhD, President of Research ...
Cached Biology Technology:Oncolytics Biotech Inc. Transfers 40-Litre cGMP Manufacturing Process for REOLYSIN(R) 2Oncolytics Biotech Inc. Transfers 40-Litre cGMP Manufacturing Process for REOLYSIN(R) 3AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy 2AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy 3Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing 2Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing 3Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing 4
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... world,s subspecies of tigers are now extinct. A new study ... a result of human activities, particularly the conversion of natural ... The study, conducted by Virginia Tech and World Wildlife ... investigate the use of different land cover types not ...
... February 29, 2012 A revealing study published in ... epilepsy is not faring well in social media. Kate McNeil ... from Twitter to provide a snapshot of how epilepsy is ... platform launched in 2006, allows its users to communicate through ...
... Wednesday, Feb. 29, 2012, Cleveland: Cleveland Clinic Children,s Hospital ... can be used to help identify children who are ... is designed to confirm the predictive value of established ... that have been completed. Thomas Frazier, Ph.D., of ...
Cached Biology News:Nowhere to hide: Study finds future of Sumatran tigers threatened by human disturbances 2Nowhere to hide: Study finds future of Sumatran tigers threatened by human disturbances 3Is Twitter reinforcing negative perceptions of epilepsy? 2Cleveland Clinic Children's Hospital launches study to genetically test for autism 2
MOUSE ANTI RABBIT T LYMPHOCTYES Immunogen: Rabbit Thymocytes...
Normal canine serum collected from healthy normal canines....
RABBIT ANTI HUMAN CYTOCHROME P450 1A1/2 Immunogen: Purified human CYP1A2 expressed in E.Coli ...
... of BAC (100+kb), fosmid (40kb), and large ... than any othe BAC vector. On command ... and easy recombinant DNA purification. Available with ... VC) vectors for the highest insert stability. ...
Biology Products: